Rituximab in anti-GBM disease: A retrospective study of 8 patients

Journal of Autoimmunity

Volumn 60, Issue , 2015, Pages 74-79

  Touzot, Maxime ^a   Poisson, Johanne ^b   Faguer, Stanislas ^c   Ribes, David ^c   Cohen, Pascal ^d   Geffray, Loic ^e   Anguel, Nadia ^f   François, Helene ^a,h   Karras, Alexandre ^g   Cacoub, Patrice ^b,i   Durrbach, Antoine ^a,h   Saadoun, David ^b,i  

^a Neuroradiology   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CHU RANGUEIL   (France)

^d Groupe hospitalier Cochin ^*  (France)

^e Service de médecine Interne CH lisieux   (France)

^f BICÊTRE HOSPITAL   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h INSERM   (France)

ⁱ SORBONNE UNIVERSITÉ   (France)

Author keywords

Goodpasture syndrome; Immunosuppression; Rituximab; Treatment

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; HEMOGLOBIN; MYCOPHENOLATE MOFETIL; RITUXIMAB; STEROID; ANTIGLOMERULAR BASEMENT MEMBRANE ANTIBODY; AUTOANTIBODY; IMMUNOSUPPRESSIVE AGENT;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LOW DRUG DOSE; MALE; OBSERVATIONAL STUDY; PLASMAPHERESIS; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; B LYMPHOCYTE; IMMUNOLOGY; KIDNEY; LYMPHOCYTE DEPLETION; MIDDLE AGED; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-GLOMERULAR BASEMENT MEMBRANE DISEASE; AUTOANTIBODIES; B-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; PLASMAPHERESIS; RETROSPECTIVE STUDIES; RITUXIMAB; YOUNG ADULT;

EID: 84931011781     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.04.003     Document Type: Article

References (18)

1. Peto P., Salama A.D. Update on antiglomerular basement membrane disease. Curr. Opin. Rheumatol. 2011, 23:32-37.
2. Salama A.D., Levy J.B., Lightstone L., Pusey C.D. Goodpasture's disease. Lancet 2001, 358:917-920.
3. Cui Z., Zhao J., Jia X., Zhu S., Jin Q., Cheng X., et al. Anti-glomerular basement membrane disease: outcomes of different therapeutic regimens in a large single-center Chinese cohort study. Med. Baltim. 2011, 90:303-311.
4. T. Hellmark, M. Segelmark, Diagnosis and classification of Goodpasture's disease (anti-GBM), J. Autoimmun. 48-49 108-112.
5. Wilson C.B., Dixon F.J. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973, 3:74-89.
6. Pedchenko V., Bondar O., Fogo A.B., Vanacore R., Voziyan P., Kitching A.R., et al. Molecular architecture of the Goodpasture autoantigen in anti-GBM nephritis. N.Engl. J. Med. 2010, 363:343-354.
7. Levy J.B., Hammad T., Coulthart A., Dougan T., Pusey C.D. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004, 66:1535-1540.
8. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N.Engl. J. Med. 2010, 363:221-232.
9. Charles P., Néel A., Tieulié N., Hot A., Pugnet G., Decaux O., et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatol. Oxf. 2014, 53:532-539.
10. Guillevin L., Pagnoux C., Karras A., Khouatra C., Aumaître O., Cohen P., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N.Engl. J. Med. 2014, 371:1771-1780.
11. Shah Y., Mohiuddin A., Sluman C., Daryanani I., Ledson T., Banerjee A., et al. Rituximab in anti-glomerular basement membrane disease. QJM 2012, 105:195-197.
12. Syeda U.A., Singer N.G., Magrey M. Anti-glomerular basement membrane antibody disease treated with rituximab: a case-based review. Semin. Arthritis Rheum. 2013, 42:567-572.
13. Wechsler E., Yang T., Jordan S.C., Vo A., Nast C.C. Anti-glomerular basement membrane disease in an HIV-infected patient. Nat. Clin. Pract. Nephrol. 2008, 4:167-171.
14. Merkel F., Weber M. Successful use of cyclosporin A in progressive anti-glomerular basement membrane nephritis. Nephrol. Dial. Transpl. 2000, 15:1714-1715.
15. García-Cantón C., Toledo A., Palomar R., Fernandez F., Lopez J., Moreno A., et al. Goodpasture's syndrome treated with mycophenolate mofetil. Nephrol. Dial. Transpl. 2000, 15:920-922.
16. Reynolds J., Cashman S.J., Evans D.J., Pusey C.D. Cyclosporin A in the prevention and treatment of experimental autoimmune glomerulonephritis in the brown Norway rat. Clin. Exp. Immunol. 1991, 85:28-32.
17. Salama A.D., Chaudhry A.N., Holthaus K.A., Mosley K., Kalluri R., Sayegh M.H., et al. Regulation by CD25+ lymphocytes of autoantigen-specific T-cell responses in Goodpasture's (anti-GBM) disease. Kidney Int. 2003, 64:1685-1694.
18. Mesnard L., Keller A.C., Michel M.-L., Vandermeersch S., Rafat C., Letavernier E., et al. Invariant natural killer T cells and TGF-beta attenuate anti-GBM glomerulonephritis. J.Am. Soc. Nephrol. 2009, 20:1282-1292.